发布求助
文献互助 智能选刊 最新文献

American journal of therapeutics最新文献

筛选
英文 中文
Tofacitinib-Associated Demyelination and Bullous Pemphigoid. 托法替尼相关脱髓鞘和大疱性类天疱疮
IF 2.9 4区 医学
American journal of therapeutics Pub Date : 2024-10-29 DOI: 10.1097/MJT.0000000000001833
Ting Su, Yuzhen Liu, Shanshan Lu, Wei Zhang, Yan Lu, Zhiqiang Yin
{"title":"Tofacitinib-Associated Demyelination and Bullous Pemphigoid.","authors":"Ting Su, Yuzhen Liu, Shanshan Lu, Wei Zhang, Yan Lu, Zhiqiang Yin","doi":"10.1097/MJT.0000000000001833","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001833","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful Treatment of Psoriasis With Apremilast in a Kidney Transplant Recipient. 用阿普司特成功治疗一名肾移植受者的银屑病
IF 2.9 4区 医学
American journal of therapeutics Pub Date : 2024-10-25 DOI: 10.1097/MJT.0000000000001825
ChaoJing Zhou, YuFei Wang, YiYun Hou, JiLiang Lu, DongHong Sun, ZhiQiang Yin
{"title":"Successful Treatment of Psoriasis With Apremilast in a Kidney Transplant Recipient.","authors":"ChaoJing Zhou, YuFei Wang, YiYun Hou, JiLiang Lu, DongHong Sun, ZhiQiang Yin","doi":"10.1097/MJT.0000000000001825","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001825","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted Therapy Outcomes in Hidradenitis Suppurativa: A Systematic Review. 化脓性扁桃体炎的靶向治疗效果：系统回顾
IF 2.9 4区 医学
American journal of therapeutics Pub Date : 2024-10-25 DOI: 10.1097/MJT.0000000000001830
Chenxingyue Zhang, Xinyi Dai, Zhiqiang Yin
{"title":"Targeted Therapy Outcomes in Hidradenitis Suppurativa: A Systematic Review.","authors":"Chenxingyue Zhang, Xinyi Dai, Zhiqiang Yin","doi":"10.1097/MJT.0000000000001830","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001830","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful Treatment of Mexiletine-Induced Methylprednisolone-Resistant DRESS Syndrome With TNF-α Inhibitor. TNF-α 抑制剂成功治疗甲泼尼龙耐药的美西律汀诱发 DRESS 综合征
IF 2.9 4区 医学
American journal of therapeutics Pub Date : 2024-10-25 DOI: 10.1097/MJT.0000000000001824
Chengzhong Zhang, Xuechen Cao, Ting Su, Jiping Xia, Meihua Zhang, Zhiqiang Yin, Yan Lu
{"title":"Successful Treatment of Mexiletine-Induced Methylprednisolone-Resistant DRESS Syndrome With TNF-α Inhibitor.","authors":"Chengzhong Zhang, Xuechen Cao, Ting Su, Jiping Xia, Meihua Zhang, Zhiqiang Yin, Yan Lu","doi":"10.1097/MJT.0000000000001824","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001824","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142493082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Meropenem-Associated Delirium. 美罗培南相关性谵妄。
IF 2.9 4区 医学
American journal of therapeutics Pub Date : 2024-10-22 DOI: 10.1097/MJT.0000000000001774
Xin-Liang Yang, Ye-Jun Chen, Wei Ou, Xiao-Hua Xie
{"title":"Meropenem-Associated Delirium.","authors":"Xin-Liang Yang, Ye-Jun Chen, Wei Ou, Xiao-Hua Xie","doi":"10.1097/MJT.0000000000001774","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001774","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transplanted Kidney Failure and Bleeding Caused by Combination of Tacrolimus, Paxlovid, and Dalteparin. 他克莫司、Paxlovid 和 Dalteparin 联合用药导致移植肾衰竭和出血。
IF 2.9 4区 医学
American journal of therapeutics Pub Date : 2024-10-22 DOI: 10.1097/MJT.0000000000001764
Xin-Liang Yang, Ye-Jun Chen, Wei Ou, Xiao-Hua Xie
{"title":"Transplanted Kidney Failure and Bleeding Caused by Combination of Tacrolimus, Paxlovid, and Dalteparin.","authors":"Xin-Liang Yang, Ye-Jun Chen, Wei Ou, Xiao-Hua Xie","doi":"10.1097/MJT.0000000000001764","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001764","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of Inhibitors of the Proximal Pathway of the Complement System in Paroxysmal Nocturnal Hemoglobinuria: A Meta-analysis of Randomized Controlled Trials. 补体系统近端通路抑制剂对阵发性夜间血红蛋白尿症的疗效和安全性：随机对照试验的 Meta 分析》。
IF 2.9 4区 医学
American journal of therapeutics Pub Date : 2024-10-22 DOI: 10.1097/MJT.0000000000001837
Milene Vitória Sampaio Sobral, Isac Ribeiro Moulaz, Victor Gonçalves Soares, Rafaela da Cunha Pirolla, Lucas Cael Azevedo Ramos Bendaham, Hilária Saugo Faria, Clara de Andrade Pontual Peres, Lubna Al-Sharif, Rebeca Carvalho Bressa
{"title":"Efficacy and Safety of Inhibitors of the Proximal Pathway of the Complement System in Paroxysmal Nocturnal Hemoglobinuria: A Meta-analysis of Randomized Controlled Trials.","authors":"Milene Vitória Sampaio Sobral, Isac Ribeiro Moulaz, Victor Gonçalves Soares, Rafaela da Cunha Pirolla, Lucas Cael Azevedo Ramos Bendaham, Hilária Saugo Faria, Clara de Andrade Pontual Peres, Lubna Al-Sharif, Rebeca Carvalho Bressa","doi":"10.1097/MJT.0000000000001837","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001837","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Characteristics and Prognosis of 39 Cases of Retinoblastoma With Optic Nerve Stump Involvement. 39例视神经残端受累视网膜母细胞瘤的临床特征和预后
IF 2.9 4区 医学
American journal of therapeutics Pub Date : 2024-10-18 DOI: 10.1097/MJT.0000000000001794
Yi-Zhuo Wang, Hui-Min Hu, Yi Zhang, Ji-Tong Shi, Jian-Min Ma, Wei-Ling Zhang, Hua-Li Gu, Yan Zhou, Dong-Sheng Huang
{"title":"Clinical Characteristics and Prognosis of 39 Cases of Retinoblastoma With Optic Nerve Stump Involvement.","authors":"Yi-Zhuo Wang, Hui-Min Hu, Yi Zhang, Ji-Tong Shi, Jian-Min Ma, Wei-Ling Zhang, Hua-Li Gu, Yan Zhou, Dong-Sheng Huang","doi":"10.1097/MJT.0000000000001794","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001794","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of Ibrutinib as Monotherapy or Combination Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL): A Systematic Review and Meta-analysis. 伊布替尼作为单药或联合疗法治疗复发/难治性弥漫大B细胞淋巴瘤（R/R DLBCL）的疗效和安全性：系统综述与元分析》。
IF 2.9 4区 医学
American journal of therapeutics Pub Date : 2024-10-16 DOI: 10.1097/MJT.0000000000001831
Yin Li, Chunfan Li, Kebing Lv, Shixuan Wang, Fei Li
{"title":"Efficacy and Safety of Ibrutinib as Monotherapy or Combination Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL): A Systematic Review and Meta-analysis.","authors":"Yin Li, Chunfan Li, Kebing Lv, Shixuan Wang, Fei Li","doi":"10.1097/MJT.0000000000001831","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001831","url":null,"abstract":"<p><strong>Background: </strong>Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease group. Ibrutinib's monotherapy or combination therapy is effective in relapsed/refractory (R/R) DLBCL. However, the treatment response in R/R DLBCL varies from 15% to 90% with different regimens, and the tolerance remains controversial.</p><p><strong>Areas of uncertainty: </strong>The efficacy and safety of ibrutinib monotherapy or combination therapy in patients with R/R DLBCL remain uncertain.</p><p><strong>Data sources: </strong>The PubMed, CBM, MEDLINE, Cochrane Library, and Embase databases were searched from their inception to July 2021.</p><p><strong>Therapeutic advances: </strong>The total complete remission rate (CRR) and overall response rate in R/R DLBCL patients treated with ibrutinib were 26% and 49%, respectively. The CRR of ibrutinib combination therapy was significantly higher than the ibrutinib monotherapy (45% vs. 19%). Moreover, the CRR of patients was 40% in double expressing lymphoma, 35% in central nervous system lymphoma, and 33% in nongerminal center B-cell-like (non-GCB) DLBCL, which was higher than the 8% in those with the GCB subtype. The pooled median PFS and overall survival were 5.57 and 10.17 months, respectively. GCB-DLBCL had the worst overall survival (5.1 months). Nevertheless, we found that combination regimens had no survival advantage compared with monotherapy (P > 0.05), indicating that combination therapy was only a transitional treatment and bridge for chimeric antigen receptor T cells or other treatments. Moreover, 12% of patients on ibrutinib combination therapy had ≥grade 3 adverse events compared with 9% on ibrutinib monotherapy.</p><p><strong>Conclusions: </strong>Ibrutinib monotherapy or combination therapy was safe and effective in treating R/R DLBCL with tolerable adverse reactions.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mesalazine-Associated Agranulocytosis. 美沙拉嗪相关粒细胞减少症
IF 2.9 4区 医学
American journal of therapeutics Pub Date : 2024-10-16 DOI: 10.1097/MJT.0000000000001832
You-Jiao Chen, Dan-Ni Luo, Zi-Meng Wan, Feng Chen
{"title":"Mesalazine-Associated Agranulocytosis.","authors":"You-Jiao Chen, Dan-Ni Luo, Zi-Meng Wan, Feng Chen","doi":"10.1097/MJT.0000000000001832","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001832","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":null,"pages":null},"PeriodicalIF":2.9,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142456222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信